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Alcoho l consumption is a significant risk-factor for mortality in patients with
sepsis. This study was carried to investigate the mechanisms by which acute ethanol
exposure alters the course ofsepsis and the effect ofTLR4 signaling.
Ethanol administration decrea~es resistance to E. coli and causes decrease in the
ability to clear bacteria both from the peritoneal-cavity as well a~ the sp leen. At early
time-point~, ethano l also suppresses the production of pro-inflammatory cytokines. TLR4
is dispensable for surviv al in E. coli sepsis but it also contributes to lethality in wild-type
mice. Although TLRs have been implicated as an important element of host defense
against infections, evidence indicates that these receptors may a lso p lay a crucial role in
the pathophysio logy ofsepsis.
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CHAPTER I
INTRODUCTION

Sepsis is a severe, complex and deadly condition which results from an infection
of the b loodstream by toxin-producing bacteria. It is a lso called Systemic inflammatory
response syndrome (SIRS) ( I). It is a state of disrupted inflammatory homeosta~is that is
often initiated by bacterial infection (2). It is a major cause of fatalities around the globe,
with around 18 million individua ls infected annua lly. In the United States, sepsis is the
th

10 leading cause of death (3). The mortality rate ranges from 20-60% depending on a
number of factors (4, 5). The deve lopment and progression of sepsis is mu lti-factorial,
and affect~ the card iovascu lar, immuno logical and endocrine systems of the body (6).
The majority of cases of sepsis are due to bacterial infections, some are due to fungal
infections, and very few are due to other causes of infection or agent~ that may cause
SIRS. Common bacterial causes of sepsis are gram-negative bacilli, for example, E. coli,

E. corrodens, P. aemginosa, S. aureus, Strepwcoccus species and Enterococcus species
(7). These infections can originate anywhere in the body and the infecting agent~ or their
toxins then spread directly or indirectly into the b loodstream (8), which helps them to
enter into almost any other organ system. SIRS results as the body tries to counteract the
damage done by these blood-borne agents (9). The most common area~ where the
infection originates are the kidneys, the liver, the lungs, the gall bladder, the bowel and

the skin. Sepsis can also be triggered by events such as pneumonia, surgery, burns, and
trauma or by conditions such as cancer or AJDS (10). In many cases, the kidneys, liver,
lungs, and central nervous system, may stop functioning normally ( 11). There may also
be a decreased blood flow to the kidneys, liver, lungs, and central nervous system ( 12).
Any person can deve lop sepsis but there are some peop le who are at a greater risk like
those with a weak immune system, those who have wounds or injuries, those with cancer,
diabetes and AIDS or elderly patients ( 13).
The complexity of sepsis makes its clinical study and it~ therapeutics di fficult.
The molecu les and processes leading to the letha l outcome of sepsis have not yet been
fu lly understood. A significant risk factor for mortality in patients with sepsis is the acute
consumption of a lcoho l (14, 15). Scientist~ have developed various anima l models in an
effort to create reproducible systems for studying sepsis pathogenesis and preliminary
testing of potential therapeutic agent~. Most of these models have shown that proinflammatory mediators play an important role in letha lity in sepsis (16, 17). However,
inhibition of these mediators in c linica l trials has not improved the outcome significantly
for sepsis patients ( 18). Efforts to study the lethality in sepsis caused by ethano l in a
mouse mode l (19) is a usefu l approach to identify mechanisms of letha lity in sepsis and
may he lp to exp lain the ineffectiveness of inhibition of any inflammatory med iators. The
study carried out here was designed to understand the differences in inflammatory
mechanisms that ex ist at a time point of 2 hours after ethanol and E. coli administration
to two different strains of mice, wi ld type C3H/He0uJ and the natura lly occurring TLR4
mutant C3H/HeJ mice. A few studies at higher time points have already been carried out
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in our laboratory which, together with results reported here, has giv en us some insight
into the different mechan isms involved.
The model used in this study is intended to represent sepsis caused by microbial
contamination of the peritoneal cavity. A variety of immunolog ical parameters are
inhibited and resistance to infection is decreased by chronic and acute exposure to
ethanol (19, 20, 21 , 22). Acute exposure to ethanol leads to suppression of inflammatory
responses in both humans (23, 24, 25) and animal (26, 27, 28) models. Patients with
sepsis caused by microb ial contamination of the peritonea l cavity following acute ethanol
exposure have reported increased rates of infection (22). E. coli is one of the most
frequently isolated bacteria from patients with sepsis ( 14). In experimental models,
decreased resistance to microbes is evident soon after challenge, suggesting that innate
immunity can be adverse ly affected by ethanol (29) Some studies regarding inhibition of
inflammatory responses as a cause of decreased resistance to microbes have been carried
out by researchers but they have been on ly a few in number ( I 9, 30, 3 I). Studies
involving the inhib ition of inflammatory responses can reveal the mechanisms by which
inflammation promotes bacterial clearance and host survival because the effects of
inhibiting a number of those mechan isms simu ltaneously are revea led by ethanol. In this
instance, inhibiting production of several mediators at the same time is beneficial because
it will provide an indication of a set of mediators that contribute to lethality. In the
present study, evidence is presented indicating mice treated with ethanol exh ib it
suppression of several mediators and processes of inflammation early which is followed
by an overgrowth of bacteria and possibly a lethal systemic inflammatory response.
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Alcoho l is the most widely abused substance in the United States and numerous
studies have revea led that it contributes to a number of adverse effect~ on the immune
system at high dosages (32). Alcohol has widespread effects on the immune system and
leaves abusers at increased risk of a variety of infections (33). Amongst the most
consistent and profound effect~ of acute ethanol exposure are decrea~ed production of
pro-inflammatory cytokines and chemokines and decreased production of leukocytes at
the sites of infection and inflammation (34, 35). Recent studies have demonstrated that
recognition of microbial components by TLR expressed by macrophages or other cell
types plays a key role in initiating inflammation (36). An increased pred isposition to
infection among patient~ with a lcoho l use problems may also mediate an association with
sepsis. Several studies have examined the association between alcohol use disorders and
the incidence of severe infections that could reasonab ly be considered sepsis (37).
Multiple human and animal studies have demonstrated abnormal immunity as a result of
alcohol exposure (4, 38). This inc lu des abnormalities in innate and adaptiv e immunity;
cellular and humoral responses; the functioning of neutrophi ls, monocytes, macrophages
and lymphocytes; and cytokine and chemokine profiles. Such di fferences could lead to an
increa~ed predi lection to infection and once estab lished an increa~ed risk of systemic
comp lications. Alteration of g lutath ione homeostasis may be an additiona l mechanism by
which alcohol abuse pred isposes septic patient~ to organ failure (39).
Immun ity has been usually divided into innate immunity and adaptive immunity.
Whi le innate immunity refers to the non-specific immune system and is mediated by the
action of macrophages and neutrophils, adaptive immunity is mainly constituted ofT and
B cells, which are clonally disseminated and known for their specificity and memory.
4

Since innate immune system lacks specificity, major focus of immune response studies
has been on T and B cells and not on innate immunity. However, there has been a recent
focus on innate immunity because of the accumulating evidence which has indicated that
insects and mammals share many facet~ of innate immune systems, and it p lays a crucial
ro le in the immune response even in mammals (40). It has also been discovered that the
innate immune system plays an advisory ro le in the adaptive immune response in
mammals (41).
The innate immune system plays a crucial role in the initial phase of microb ial
detection. The discovery of toll-like receptors (TLR's) ha~ revolutionized our
understanding of how innate immune system recognizes di fferent micro-organisms and
how innate immunity gets activ ated. To ll-like receptors are proteins, wh ich are composed
of leucine rich repeats, involved in ligand recognition and a toll/interleukin-I receptor
(TIR) domain, involved in signaling that p lay a critical role in the innate immune system.
They activ ate the innate immune system by identifying specific patterns of microbial
components ca lled the pathogen-a~sociated molecular patterns (PAMP's) that activates
the production of proinflammatory cytokines and therefore initiate pathogen-specific
immune responses (42, 43). Each toll- like receptor has a unique domain that a llows
specific ligand recognition. So far, thirteen TLRs (TLRI to TLR13) have been identified
in humans and mice together. They a lso have di fferent adapters to reciprocate to
activation and are located both at the cell surface as we ll as on interna l ce llular
components. Mye lo id differentiation primary response gene (MyD88) is essential for
most TLR 's signaling and involved in nuclear factor-8 (NF-kB) and mitogen-activated
protein kinase (MAPK) activation and pro-inflammatory gene expression (44). TLR4 is
5

one of the thirteen toll-like receptors. It is a protein in humans encoded by the TLR4 gene.
It p lays a fundamental role in the recognition of lipopolysaccharide (LPS) from gram-

negativ e bacteria. Once the innate immune system is activated by the microbial ligands,
immune cells can produce signa ling molecules called cytokines which cause
inflammation and in the case of bacteria, it might be phagocytosed and digested (45). It is
quite interesting that to ll-like receptors seem to be invo lv ed in the cytokine production
and ce llular activation on ly in response to micro-organisms and do not play any maj or
ro le in their adherence and phagocytosis. Most of the responses activ ated through TLR4
and other to ll-like receptors are inhibited by acute ethano l exposure and it is be lieved that
this contributes to decreased resistance to infection (19, 46, 47, 48). To test this
assumption, effects of ethanol in wi ld-type mice were compared to it~ effects in mutantTLR4 mice. The results demonstrate that inhibition of TLR4 signaling by ethanol is
probab ly not a maj or cause of decreased resistance to sepsis.
C3H/HeJ is a mutant mouse strain that has been found to be hyporesponsive to
lipopolysaccharide (LPS) (49). The defective response to LPS in the C3 H/HeJ mice is
controlled by a single autosoma l gene (lps) on mouse chromosome 4 (50, 5 I). The lps
gene ha~ been cloned and shown to encode TLR4. The TLR4 mutation in C3H/HeJ is a
mis-sense point mutation which resu lts in the substitution of histidine for a proline that is
highly conserved among TLR fam ily members (52, 53, 54). Mice deficient in the TLR4
gene have a lso been generated by gene-disruption techn iques (54). Macrophages and 8cells from TLR4 knock-out mice have been shown to be hyporesponsiv e to LPS to a
similar extent as C3 H/HeJ mice, endorsing that TLR4 is required for LPS signa ling.
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A study carried out by our laboratory earlier has shown that LPS is a major
contributor to the induction of cytokines and chemokines by E. coli and that the
production of cytokines and chemokines is approximate ly 2 to 15- fold greater in
C3H/He0uJ mice than in the TLR4 mutant C3H/HeJ mice (55). Thus the poor response
of C3H/HeJ mice to LPS substantially decreases response of these mice with regard to all
tested cytokines and chemokines. This study has a lso shown that ethanol alone does not
induce these cytokines and chemokines to concentrations higher than in contro l mice.
Cytokines are signaling molecules released by di fferent types of cells and p lay an
important role in innate and adaptive immunity. Cytokines bind to specific ce ll-surface
receptors and produce intracellu lar signaling that can up- or down-regu late genes,
transcription factors, and even other cytokines and cytokine receptors. The effect of a
particular cytokine is dependent upon the abundance of the cytokine, the presence of a
comp lementary cell surface receptor, and downstream signa ls that are activated by
receptor binding (56). Overproduction of cytokines can trigger a cytokine storm which is
a potentially fatal condition. A distinctive feature of cytokines is that they are usually
produced only in response to stimu lation (57). Usually their production cycle lasts a few
hours to a few days in the norma l state, but in an infectious state, it is possib le for
cytokine production to be pro longed (58). Basically all ce lls can produce cytokines in
response to various stimu li (59). The type of cytokines a cell produces depends entire ly
on the kind of stimulus, it~ nature and the presence of other factors like other cytokines,
hormones, etc (60). Potency is a key attribute of cytokines (61 ). They are bioactive at
very low concentrations because of the high affinity of their receptors and signaling does
not require high receptor occupancy. Another interesting feature of cytokines, known as
7

pleiotropy, is the ability ofa single cytokine to perform di fferent actions on di fferent cells
(58, 6 I). Also, the ability of di fferent cytokines to perform a particu lar function is another
important characteristic of cytokines. This is known a~ ' redundancy' in cytokine
function. The most abundant sources of cytokines are the macrophages, T cells, and mast
cells (61 ). In addition to immune signa ling, cytokines a lso p lay a ro le in various other
functions like growth, cell division, apoptosis, repair, fibrosis, etc (64).
Cytokines have been estab lished to play a critical role in the initiation of
inflammatory responses (65). Inflammatory cytokines can be mainly c lassified into two
groups, acute inflammatory cytokines and chronic inflammatory cytokines (66). The
cytokines involved main ly in acute inflammation are IL-I, IL-6, IL-8, IL-11 , TNF-a, GCSF, GM-CSF and other chemokines. The chron ic inflammation med iating group of
cytokines can be subdivided into cytokines involved in humora l responses such as IL-4,
IL-5, IL-6, IL-7, and IL-13, and those responsible for cellular responses such as IL-I, IL2, IL-3, IL-4, IL-7, IL-9, IL-10, IL-12, interferons, TGF-~, and TNF-a and TNF-~.
Inflammation in the acute pha~e is characterized by increa~ed blood flow and va~ular
permeability and there is accumulation of leukocytes and cytokines. However, the
chron ic phase is defined as the process of specific humoral and cellu lar immune
responses to the microbes responsib le for the infection or inj ury. Cytokines function
through a complex set of functions that are both synerg istic as we ll as antagonistic
interactions and produce negative and positive regulatory effect~ on di fferent target ce lls
(152).
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Acute inflammatory cytokines
Cytokines involved in acute inflammatory reactions include IL-I, IL-6, IL-8, IL-

i 1, TNF-a, G-CSF, GM-CSF and other chemokines. Among these, the primary cytokines
responsible for acute inflammation induced in anima ls by microbia l lipopolysaccharide
and other mediators ofseptic-shock are IL-I and TNF-a ( 152).

Interleukin- I
The leading producers of interleukin-I are macrophages, monocytes, fibrob lasts,
dendritic cells, T cells and B cells. IL-I cytokines p lay a very important part in the
inflammatory response of the body against infection. IL-I helps in the production of
histamine from mast ce lls at the inflammatory site, which elicits early va~odi lation and
increase of vascular permeability (68, 69, 152). Fever can also be triggered by IL-I
cytokines by enhancing the production of prostag landin E2 by the vascular endothelium
of the hypothalamus (67) and can stimulate T ce ll proliferation. They are also important
in the regulation of Hematopoiesis.

lnterleukin-6
lnterleukin-6 is secreted mainly by mononuc lear phagocytes, T cells and
fibroblasts (73, 74, 75). It is one of the most important mediators of fever and the acute
phase immune response. It also acts as a B cell growth factor and promotes their
maturation into antibody-producing p lasma cells and also plays a part in T cell activation
and differentiation. It has been observed that there is an up-regulation in the production
of IL-6 in a variety of chronic inflammatory and autoimmune disorders such a~ type I
9

diabetes, thyroiditis, rheumatoid arthritis (76, 77), system ic sc lerosis (78), mesangial
proliferativ e glomerulonephritis and psoriasis, cardiac myxoma, rena l cell carcinoma,
multiple mye loma, lymphoma, and leukemia (76, 152). It~ ro le as an anti-inflammatory
cytokine is mediated through its inhib itory effect~ on IL-I and TNF-a, and activation of
IL- IO (152).

lnterleukin-11

Interleukin-I I is mainly produced by bone marrow stromal cells and fibroblast~.
Its main ro le inc lu des increa~ed p late let secretion, induction of acute pha~e protein
secretion, stimulation of T-cell dependent 8 -cell immunog lobul in production and
induction of interleukin-6 expression by CD4+ T cells (80, 152). IL-I I has also got a lot
of functional similarities with IL-6 and it can even work as a substitute to IL-6 for the
generation of certain plasmacytoma cell lines (79).

lnterleukin-8 and other chemokines

lnterleukin-8 is mainly produced by endothe lial and epithe lial ce lls, mononuc lear
phagocytes, antigen-activated Tcells, and even some neutrophi ls (81, 83). It is one of the
most thoroughly studied chemokine and it~ main inflammatory effect lies in it~
chemotactic effect~ on neutrophi ls and its ability to generate granu locyte activity. It's
primary function is to recruit neutrophi ls to phagocytose the invading antigen which
trigger the toll-like receptors. lnterleukin-8 and other chemokines are a part of a
chemotactic cytokine fami ly and are in-charge for the chemotactic migration and
activation of monocytes, lymphocytes, basophils, eosinophils and neutrophi ls at the sites
IO

of inflammation (81, 82). Chemokines have been implicated in inflammatory conditions
from acute neutrophi l-mediated conditions such as acute respiratory distress syndrome to
allerg ic asthma, arthritis, psoria~is, and chronic inflammatory disorders ( 152). IL-8 can
be detected in synovial fluid from patients with various inflammatory rheumatic diseases
(84, 85), and mucosa] levels ofIL-8 are elevated in patients with active u lcerative co litis
(86, 152).
Some other chemokines like RANTES, MCP-1 , MCP-2, MIP-1 , and MIP-2 also
play important roles in acute inflammation through their mutual effects on ce ll migration.
MCP-1 is a chemokine which is found in the supemat.ants of blood mononuclear cells. Its
production in monocytes is enhanced by inflammatory cytokines. MIP-la and MIP-1~
induce monocyte and T lymphocyte migration. MIP-la, MCP-1 , and MIP-2 have been
imp licated in the pathogenesis of rheumatoid arthritis where they are believed to recruit
mononuc lear ce lls into the inflamed regions of the synovium (87, 152).

lnterleukin-17

Interleukin-17 is mainly produced by T-helper cells. The most important role of
IL-17 is its involvement in inducing and mediating proinflammatory responses. IL-17 is
commonly associated with allergic responses and its biologica l activ ities include
stimulation of many other cytokines like IL-6, IL-8 and various other chemokines (89).
The functioning of IL-17 is also essential to a subset of CD4+ T-Ce lls called T helper 17

(Tb17) ce lls. Latest studies have also shown that one of the mo lecules that can serve as a
mediator of the T ce ll response to pathogens may be IL- 17 (90, 91, 152).

II

Tumor necrosis factor

Tumor necrosis factors-(TNF) a and~ are main ly produced by macrophages, mast
cells, fibrobla~ts and some T-ce lls (70, 71, 72). Both TNF-a and TNF-~ bind to common
receptors on the surface of target ce lls and exhib it several common b io logical activ ities.
TNF- a can induce fever through the stimulation of PGE2 synthesis by the vascular
endothelium of the hypothalamus and also by inducing re lease of IL-I (67). TNF- a is
also responsible for the induction of acute phase reactant protein production by the liver.
Large amounts ofTNF are released in response to lipopolysaccharide during sepsis with
Gram-negative organisms. The systemic relea~e of these cytokines has been shown to be
responsible for the fever and hypotension that characterize septic shock (72, 152).

Eotaxin

Eotaxins are molecu les produced by cytokine-stimu lated epithelia l and
endothelial cells as well as IL-3- stimulated eosinophils. They are specific chemoattractants for eosinophils. Eotaxin is implicated in allergic responses and inflammatory
bowe l disease where its mRNA levels are markedly elevated, especially in ulcerative
colitis (88,152).

Colony stimulating factors

Colony stimulating factors (CSF's) are produced large ly by monocytes, T-ce lls,
fibrobla~t~ and endothelia l ce lls. They are usua lly named according to the target cell type
whose colony formation in soft agar-<:u ltures of bone marrow they induce (92). Two
types ofCSF's, granu locyte-CSF (G-CSF) and granulocyte macrophage-CSF (GM-CSF)
12

are involved in acute inflammation. Both these CSF's can stimulate neutrophi ls, whi le
GM-CSF can also activate effector functions of eosinophils and mononuclear phagocytes
(152).

Chronic inflammatory cytokines
Cytokines usua lly responsib le for chronic inflammatory processes can be divided
into two groups, those involved in humoral inflammation and those involv ed in cellular
inflammation. The group of cytokines responsible for humora l inflammation inc lu des IL3, IL-4, IL-5 , IL-6, IL-7, IL-9, IL-10, IL-13 and transforming growth factor-~ (TGF-~),
and those involved in cellular inflammation include IL-I , IL-2, IL-3, IL-4, IL-7, IL-9, IL10, IL-12, interferons (IFNs), IFN-

inducing factor (IGIF), TGF-~, and TNF-a and

TNF-~ ( 152). Chron ic inflammation usually develops after acute inflammation and
mainly lasts for weeks or months. During chron ic inflammation, cytokine interactions
take place and as a result, there is transfer of monocytes to the site of inflammation where
macrophage activating factors (MAF), such a~ IFN- , MCP-1, and other molecu les then
activate the macrophages whi le other factors, such as GM-CSF and IFN- , retain them at
the inflammatory site (93). The macrophages play an important role in the inflammatory
processes by chronically mu ltiplying low leve ls of IL-I and TNF that result in fever,
sleepiness, anorexia and leukocytosis (152).
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Bumoral inflammatory response cytokines

Interleukin-9

lnterleukin-9 is cytokine produced by CD4+ T helper (TH2) cells and some 8-cell
lymphomas. It stimulates cell proliferation and prevent~ apoptosis. It ha~ a regulatory role
in the body as it has been shown to inhibit lymphokine production by IFN- -producing
CD4+ T cells. It a lso promotes the growth of CD8+ T ce lls (94), enhances the production
of immunoglobu lins by B ce lls and also plays a role in the proli feration of mast cells (95,
152).

Interleukin- to

The leading producers of Interleukin- IO are the monocytes, CD4+ T ce lls,
activated CD8+ T ce lls and a lso some lymphocytes (96). IL- IO plays a key role in many
important b io logical functions. It effects include the down-regulation of TH 1 cytokines,
MHC cla~s II antigens, and co-stimulatory molecu les on macrophages (97). It also
enhances B ce ll survival, proliferation, and antibody production. It is a lso known as a
cytokine synthesis inhibitory factor (CSIF) because it inhib its IFN-

production by

activated T cells. Since IL- IO can be produced byTH2 ce lls and inhibit~ TH, function by
preventing TH 1 cytokine production, IL- IO is considered a T cell cross-regu latory factor
and is therefore also known as an "anticytokine" (98). It is also produced by cytotoxic Tcells to inhib it the actions of NK ce lls during the immune response to vira l infection
(152).
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lnterleukin-13
lnterleukin-13 is produced main ly by T-helper type-2 (T H2) cells. IL-13 enhances
monocyte and B lymphocyte di fferentiation and proli feration, increases CD23
expression, and induces IgG4 and lgE c lass switching ( 100). It also displays antiinflammatory activities by inhibiting the production of inflammatory cytokines, such as
IL-I~, IL- 8, IL-6 and TNF-a (99). Inhibition of inflammatory cytokine production is also
a characteristic of two other cytokines produced by T H2 lymphocytes, name ly IL-4 and
IL- IO (152).

Transforming Growth Factor-8
The transform ing growth factor-~ is a cytokine which is present in three isoforms
known as the TGF- ~I, ~2, and ~3. This cytokines fam ily is main ly produced by
monocytes, T cells and p latelets. TGF-~ is usua lly stored in platelets and is re leased at the
site of inj ury upon degranulation. It then attract~ monocytes and other leukocytes to the
injury site and participates in the initial step of chronic inflammation. It a lso regulates its
own production and the expression of integrins resulting in enhanced cell adhesion. TGFinhib its T ce ll and NK cell proliferation and activation and may p lay an important role
in inflammation (I 01). It inhibit~ co llagenase production and it may also result in
unregulated tissue repair if the expression is pro longed. Studies have shown that it may
have a ro le in mesangial proliferative g lomerulonephritis, diabetic pulmonary fibrosis,
and system ic sclerosis ( I 02, I 03, 152).
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Cellular inflammatory response cytokines

Interleukin-12
lnterleukin-1 2 is secreted by macrophages, dendritic ce lls, activated B cells and
other antigen-presenting cells (APS 's). It was previous ly also known as natural killer cell
stimulatory factor (NKSF) and cytotox ic lymphocyte maturation factor (CLMF). IL-12
plays an important role in the activities of natura l ki ller cells and T lymphocytes. It helps
in the enhancement of the cytotoxic activity of NK ce lls and CD8+ cytotox ic T
lymphocytes, in the induction of IFN-

production by NK cells and T cells, and

inhibition of IgE synthesis by IL-4-stimulated lymphocytes ( I 04, 105, 106). But it~
production is also inhib ited by IL-4 and IL-IO cytokines. The stimu latory effect of IL-12
on THI development is countered by IL-4, a cytokine which promotes TH2 cell
development. Therefore, IL-12 p lays a key ro le in cell-mediated inflammation and also
contributes to the regulation of immunoglobulin production ( 152).

Interleukin-JS
lnterleukin-15 is produced by many types of ce lls inc lu ding the monocytes and T
lymphocytes. It was originally discovered as a mo lecule having a T ce ll stimulatory
activity ( 107). It regulates T lymphocyte and NK cell activation and proliferation, as well
as CTL and LAK activity (95). It p lays a role in the enhancement of B ce ll proliferation
and immunoglobulin production ( 108). It also acts as a T lymphocyte chemo-attractant.
Various studies have a lso shown that IL-15 may have a role in the induction and
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activation of T lymphocytes in the synovium of patient~ with rheumatoid arthritis where
its levels have been found to be elevated ( I 09, 152).

Interferons

Interferons are a group of cytokines wh ich are produced mainly by lymphocytes.
They play an important ro le in a variety of functions like the activation of immune cells,
such as natural killer cells and macrophages, increasing the recognition of infection or
tumor cells by the up-regulation of antigen presentation to T lymphocytes and increasing
the ability of uninfected host cells to resist new infection by microbes (110). The type I
interferons inc lu de IFN-a and IFN-~. These interferons possess anti-escalativ e and antiviral properties and up-regulate MHC class I expression. IFN-

is another type of

interferon and is known to stimulate MHC class I and II expression and also stimulates
various effector functions of mononuclear phagocytes. IFN-a and IFN-~ have a common
receptor while IFNshown that IFN-

has a distinct and specific cell surface receptor. Studies have

p lays a role in the pathogenesis of various autoimmune and chronic

inflammatory conditions ( 11 I) like Type I diabetes me llitus (113, 114), adjuvant-induced
arthritis (115), and experimental cerebra l malaria ( I 16). In experiments with IFNknock-out mice, it has been observed that one of primary functions of IFN-

in vivo

appears to be the activation of macrophages to ki ll intracellu lar pathogens such as
mycobacteria (117, 152).
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CHAPTER)]
MATERIALS AND METHODS

Mice
Two different strains of mice, C3H/HeJ and C3H/HeOuJ were used. C3H/HeJ
mice have a mutant TLR4 gene wh ich yields a protein that is non-responsive to bacterial
lipopolysaccharide, which is the naturally occurring ligand for TLR4. The C3H/HeOuJ
mice are the wi ld-type strain wh ich matches the C3H/HeJ strain at every locus other than
TLR4. All the mice were obtained from Jackson Labs (Bar Harbor, Maine). They were
allowed to acclimatize and to recover from the shipping stress for at least 2 weeks before
use in experiments at 8-12 weeks of age. Female mice were used because males fight
when group housed and this causes stress, which can affect the result~. All the mice were
housed in filter-top shoebox cages with 5 mice per cage in a temperature

F) and

humidity (40-60%) controlled environment. Because of the decreased resistance to some
microbes, food, water and bedding for the mice were autoclaved before use for a ll the
mice. Sentinel mice housed in the same room as the mice used in this study were negative
for all common infectious agent~ during the period of this study. The laboratory animal
facility and anima l research program at M ississipp i State University are accredited by the
American Association for Accreditation of Laboratory Animal Care. M ice were housed
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and used in accordance with the National Institute of Hea lth and Mississippi State
University regu lations.

Administration of ethanol

Ethanol wa~ administered as a 32% v/v (volume/volume) solution in tissue
culture-grade water by oral gavage using an 18-guage stain less steel gavage need le. All
the mice were treated with a dosage of 6g/kg ethanol. This dose yie lds a blood ethanol
concentration of--0.4% which is similar to the blood ethanol levels that occur in ethanol
dependent humans (1 20). Although this blood concentration represents the high-end of
the range typ ically observed in ethano l-dependent persons or binge drinkers,
concentrations in this range are not rare. In the naive mice, water alone wa~ used by
gavage to contro l for handling and dosing related stress.

Administration of E. coli

Viable E. coli, log phase, grown in LB broth was administered intraperitoneally.
The dosage of E. coli was 2 x 108 per mouse, which is similar to the dosages used by
other investigators.
The£. coli strain used in this study was isolated from the co lon of one of the mice
in our specific pathogen free colony. It was characterized by the College of Veterinary
Medicine Clinica l Microbiology Laboratory as a non-pathogenic E. coli. As expected for
non-pathogenic bacteria, mice can clear a large number without mortality. However, 2 x
108 per mouse routinely yie lds I 0-20% mortality, indicating that this is a sufficient
dosage to identify decrea~ed resistance to sepsis, which would cause higher mortality.
19

Bacteria for the experiment were prepared starting with a frozen vial, wh ich was one of a
set frozen at the same time from the same culture. Bacteria were in log growth phase,
which was indicated by a spectrophotometer OD at 650nm and dosages were also
estimated using same OD measurements and a standard growth curve. This number was
verified by serial dilutions and plate count~ and va lues were always within 10% of the
nomina l count. This mode l is expected to be representative of sepsis in humans that
begins with the loss of gastrointestinal barrier function wh ich is usua lly caused by
trauma, appendicitis, dimin ished liver function etc. In human peritonitis, a single species
of bacteria often predom inates and in approximately half of the ca~es, E. coli is the
species isolated in b lood cultures (121, 122). Thus, administration of a single strain of
indigenous E. coli in our mode l allows more controlled conditions than cecal ligation and
puncture but yields peritonitis and sepsis similar to that observed in humans.

Experimental Design

Experiment was designed with a group size of 5 mice. Both the strains of mice
were div ided into 3 groups each and were grouped on the ba~is of treatment administered.
The first group of mice in each strain remained untreated and was referred to a~ the naive
group. This group served to confirm that the anticipated inflammatory changes were
induced by E. coli. The second group in each strain was treated with E. coli only and the
third group was treated with both E. coli and ethanol.
Mice were treated by gavage with ethanol or water and immed iate ly cha llenged
with E. coli (2x I 0 8 per mouse). Different groups of mice were anesthetized by inhalation
of halothane at 2 hours after E. coli challenge.
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Sampling of blood, peritoneal lavage and extraction of spleen

Blood samples were obtained retro-orb itally while the animal was under
halothane anesthesia. Samples were collected and the serum was removed after
centrifugation. Serum was refrigerated unti l needed for analysis. After euthana~ia by
continued inhalation of halothane, peritoneal lavage was performed by inj ection of 1ml of
PBS. The abdominal area was massaged to distribute the fluid and to mix the contents of
the peritoneal cavity. The skin was dissected away to reveal the peritoneum and a sample
from the peritoneal cavity was withdrawn using a syringe with a 25-guage needle.
Samples of this fluid were used to quantify bacteria by making serial dilutions in LB
agar, kept at 45°C to prevent solidification and plating and perform ing the plate counts
manually. The rest of the peritonea l fluid sample was centrifuged to remove cells and
debris and the supematants were used for di fferential cell counts using a Cou lter Zl
particle counter, for cytospin preparations followed by Wright Giemsa staining and
di fferential cell counts at 600x magnification under an e lectronic microscope. The rest of
the fluid in all of the samp les wa~ refrigerated at -20° C unti l needed for cytokine and
chemokine assay. Spleen from a ll the mice was also collected and weighed and then
divided into three almost-equa l part~ and stored in di fferent vials at -80° C to quantify
bacteria by seria l dilutions in LB agar kept at the same conditions as the intra-peritoneal
fluid, and the other two parts were a lso stored at -80°C for proteom ics and RNA analysis
respectively.
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Quantifying bacteria

After anesthesia, peritoneal lavage was perfonned on all the mice. Samples of this
fluid were used to quantify the bacteria by making serial dilutions in LB agar, which was
prepared fresh and held at 45°C to prevent its solidi fication. Plating wa~ done and p late
counting was perfonned.

Cytospin Counts

Peritoneal lavage fluid samples were a lso used for cytospin preparations by using
Wright Giemsa staining and di fferential ce ll counts at 600x magnification with an oil
immersion lens. Cells with three or more bacteria associated were referred to as cells with
E. coli and ce lls with less than three£. coli were referred to as cells without£. coli. This

was designed to account for the possibility that some of the bacteria that appeared to be
intracellu lar might actually be on the cell surface.

Cell Counts

The number of nuc leated cells in peritoneal fluid as we ll as spleen was
detenn ined by using samp les of peritoneal lavage fluid with cells suspended and samples
of spleen. Manual lysing reagent was added to lyse the cytoplasmic membrane, leaving
only nuclei to be counted. Count~ were detennined using a Coulter ZI particle counter.

Cytokine assays

Cytokine and chemokine concentrations in peritoneal lavage fluid were quantified
using

kit~

from

Millipore

Corporation,
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ca lled

MJLLIPLEX

MAP

Mouse

Cytokine/Chemokine - Premixed 32 P lex, 96-Well Plate Assay using standards for each
cytokine and chemokine.

Flow cytometry analysis
Spleen samp les were used for carrying out flow cytometry using a BO
Biosciences FACS Ca libur flow cytometer which is a multico lor benchtop flow
cytometry system that is capable of both analyzing and sorting.
The di fferent markers used include the CD4, the CD8, the NKl. l and the ce lls
that express MHC

n. The ce lls labe led by these markers are T helper lymphocytes

(CD4), cytotoxic T lymphocytes (CD8), NK cells (NKI. 1), B lymphocytes (MHC ll) and
macrophages (MHC TI).

Statistical analysis
All the data analysis was performed using Prism 5 .0 software (GraphPad, San
Diego, CA). Data with continuous variab les were analyzed by analysis of variance
(ANOVA), followed by Newman-Keuls post-hoc test to identify di fferences in group
means. Means with a P va lue of .05 or less were considered significantly di fferent.
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CHAPTER Ill
RESULTS

Acute administration of ethanol suppressed the immune response in both the wi ld
type (C3H/He0uJ) and TLR4 mutant (C3 H/HeJ) mice. The resu lts in Figure I indicate

the number of viable E. coli isolated at 2 hours after challenge from the peritonea l cavity
of control and mutant mice. The resu lts demonstrate that ethanol suppressed the clearance
of bacteria from the peritoneal cavity of both the strains of mice. Similarly, the result~ in
Figure 2 indicate the number of viable £. coli isolated from the spleen at 2 hours after
challenge from the peritoneal cavity of both the wi ld type and mutant mice. The result~
here show a similar pattern a~ the peritoneal fluid; however, the numbers are much less
than in the peritoneal fluid. Both these resu lts reflect the suppression of the clearance of
bacteria by ethanol. It should be noted that 2 hours is very early in the process of
infection, and it has been reported previously that the differences in bacterial numbers get
larger over time in ethanol treated and control mice (55). In the peritonea l fluid there was
a slight increase in bacterial count~ in TLR4 mutant mice as compared to control mice.
In contra~!, a smaller number of bacteria were noted in the spleen of mutant ethanol

treated mice than in wild type ethanol treated mice.
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Figure 3 shows the cell count~ of the peritoneal fluid samp les from both the
strains. The results in Figure 4 indicate the cell counts of the sp leen samples. There was
no significant effect of ethano l on cell number in either mouse strain, and there was no
significant di fference between wild type and TLR4 mutant strains.
The resu lts in Figure 5 & 6 indicate the type of cells in the peritoneal cavity of the
mice. As the figures show, most of the ce lls in the peritoneal cavity were macrophages
and there were a small percentage of lymphocytes present in both the control as well as
mutant mice. Neither E. coli nor ethano l had a significant effect on the percentages of
these ce lls. There was also no significant difference between strains.
The effect~ of ethano l on cytokine and chemokine production at a time point of 2
hours after E. coli cha llenge are indicated in Figures 7 (a)-(y). The production of a ll of
the cytokines and chemokines, except IL-IO and MlP-2, was significantly decreased by
ethanol treatment just before the£. coli challenge in wi ld type mice. In contrast, severa l
cytokines and chemokines (IL- I ~, MJP-2, IL-10, IL-17, LIF, RANTES, MlP-la, TNF-a,
Eotaxin, and GM-CSF) were not significantly altered by ethanol in TLR4 mutant mice.
This provides the first evidence that most cytokines and chemokines induced through
receptors other than TLR4 are not significantly decrea~ed by ethano l.

The TLR4

mutation in C3H/He.J mice significantly decreased production of most of the 25 cytokines
and chemokines tested. Only MJG, M-CSF, G-CSF, MCP-1 , IP-I 0, IL-6, IFN- , and
Eotaxin were not significantly di fferent in mutant as compared to wi ld type mice.
Ethanol caused a significant increase in cytokine or chemokine production only in
the case of IL-IO in wi ld type mice and IL-17 in the TLR4 mutant strain.
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Figures 8 (a)-(d) represent the flow cytometry data obtained by carrying out flow
cytometry analysis of the sp leen samples from both the wi ld type and mutant strains of
the mice. Figure 8a shows the CD4 cell percentages, Figure 8b represent~ the CD8 cell
percentages, Figure 8c shows the NK I. I cell percentages and Figure 8d shows the
percentage of ce lls that express MHC n. The ce lls labeled by these markers are T helper
lymphocytes (CD4), cytotoxic T lymphocytes (CD8), NK cells (NKl.1), B lymphocytes
(MHC n) and macrophages (MHC n). Ethanol did not significantly affect the percentage
of any of these cells types. However, the TLR4 mutant mice had a modestly higher
percentage of CD4, CD8, and MHC I] positive cells than wi ld type mice.
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Peritoneal Fluid Bacterial Count

d

Figure I

Number of viable E. coli iso lated at 2 h after challenge from the peritoneal
cavity of control (C3H/He0uJ) and mutant (C3H/HeJ) mice

Spleen Bacterial Count
C

Figure 2

Number of viable E. coli iso lated at 2 h after challenge from the Spleen of
control (C3H/He0uJ) and mutant (C3H/HeJ) mice

27

Peritoneal Fluid Cell Count
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Figure 3

Cell Counts at 2 h a fter challenge from the peritoneal cavity of control
(C3 H/He0uJ) and mutant (C3H/HeJ) mice

Spleen Cell Count
8 .0x10 7

a

6 .0x10 7
4 .0x10 7
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Figure 4

Cell Counts at 2 h a fter challenge from the Spleen of control (C3H/He0uJ)
and mutant (C3H/HeJ) mice
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Macrophage Count
100

Figure 5

Indicates the percentage of macrophages in the peritoneal cavity of the mice
2 h after E. coli challenge

Lymphocyte Count
25

Figure 6

a

Indicates the percentage of Lymphocytes in the peritoneal cavity of the mice 2
h after E. coli cha llenge
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(a)-(y) Indicate the effects of ethano l on cytokine and chemokine production
at a time point of 2 h after E. coli challenge
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(a)-(d) Represent the flow cytometry data obtained by carrying out flow
cytometry analysis of the sp leen samp les from both the control as well a~ the
mutant strains of the mice
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CHAPTER IV
DISCUSSION

Alcoho l consumption has long been recognized as a risk factor for infections.
Previous studies in our laboratory and other laboratories have clearly demonstrated that
acute ethanol treatment interferes with the innate immune response. The effects reported
here occurred at re levant ethanol concentrations. The resu lts presented here demonstrate
that mice treated with ethanol and then challenged with non-pathogenic £ . coli
intraperitoneally show decreased c learance of bacteria by macrophages and decreased
cell counts in both the peritoneal cavity and the spleen. The production of most proinflammatory cytokines and chemokines was also suppressed as was the attraction of
neutrophi ls to the peritoneal cavity. These results indicate that ethanol inhib its the initial
inflammatory response to£. coli, which, in tum, decreases the clearance of bacteria in the
first few hours after the challenge.
Many studies have reported that ethanol inhibits TLR signaling ( 123, 124, 125,
126) and it seemed like ly that this was invo lved in the decreased resistance to infection
associated with acute ethano l exposure. However, the resu lts presented in an earlier study
done in our lab (55) indicate that survival was enhanced in the absence of ful ly functional
TLR4, therefore inhibition of TLR4 signa ling as the major mechanism by which ethanol
suppresses resistance to sepsis seems un like ly. However, it is quite possib le that
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inhibition of TLR4 signa ling either by ethano l or TLR4 absence does p lay an important
ro le in decreased resistance to lower dosages of bacteria, as is the case with C3H/HeJ
mice ( 127) and that clearance of higher dosages of bacteria could be delayed (128) even
if ultimate ly effective. Studies have a lso shown that C3 H/HeJ (TLR4 mutant) mice do not
survive as we ll as wild type mice when a low dose of entero-pathogenic £. coli or a sublethal cha llenge dose of bacteria is administered ( 129, 127). However, when mice were
treated with a greater letha l dose of bacteria, a much higher percentage of C3 H/HeJ
mutant mice surviv ed than wild type mice (55). Similar results were also reported very
recently (130), indicating that TLR4 mutant mice have increa~ed resistance to a letha l
outcome in E. coli sepsis caused by a high dosage of£. coli. Thus, it seems like ly that the
role ofTLR4 in resistance to sepsis and letha lity in sepsis depends on the initial cha llenge
dose of bacteria.

In addition to the TLR4, there are various other receptors (130), both cytoplasmic
as well as membrane bound that respond to LPS and there are other TLRs that respond to
other component~ of gram negative bacteria. Therefore, it is quite possible that in the
absence of TLR4, these other receptors med iate enough response to lead to bacterial
clearance but not enough to over-produce the inflammatory mediators. The resu lts
presented here with regard to cytokine and chemokine production in TLR4 mutant and
wild type mice support this idea.
The findings of the current study demonstrate that ethanol suppresses the
production of most of the cytokines and chemokines and in fact, on ly wild-type mice
produced more IL-IO when treated with ethanol and also IL-17 production was not
suppressed in the mutant mice when treated with ethanol. These result~ are in agreement
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with an earlier study by our laboratory (131) and other studies (132, 25) which have also
shown that ethano l suppresses cytokine and chemokine induction. It has also been
established that response of macrophages to whole gram negative bacteria invo lves
responses through several TLRs that are also induced by gram-positive bacteria and a
response through TLR4 induced by LPS of the gram-negative bacteria ( 133). Thus it is
not surprising that ethano l, which suppresses responses through most or a ll TLRs, would
suppress resistance to the gram-negative bacterium E. coli. These resu lts support the idea
that the suppression of pro-inflammatory cytokines, the increase in IL-10 and probab ly
other changes are sufficient to d iminish host resistance. This is further supported by the
observation that the effects of ethanol on cytokine concentrations in mice cha llenged with
E. coli were similar to the effects of ethanol on LPS-induced cytokine production ( 134).

In a prev ious recent study done in our lab (55), it has been shown that mice did not begin
to die unti l about 20 h approximately after treatment, it seems possible that ethanol
induced decrease in pro-inflammatory cytokines and chemokines and the substantial
increa~e in IL-10 concentration allow uncontrollable rep lication of E. coli unti l the effect~
of ethanol subside and fatal cytokine induced septic shock ensues.
The suppression of cytokines and chemokines wa~ somewhat selective with
regard to the amount of suppress ion but all pro-inflammatory cytokines tended to be
decreased by ethano l treatment. The resu lts from the cytokine and chemokine study also
showed various patterns in response to the di fferent treatment~ by both the control as well
as the mutant mice. Whi le a group of cytokines (IFN- , IL-la, IL-6, IL-9, IL-13, IL-15,
IL-12p40, IL-12p70, MlP-2, M-CSF, G-CSF, MIG, MCPI , LDC, IP-10) wa~ suppressed
by the treatment of ethanol in both the strains of mice, it didn't seem like TLR4 absence
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had any maj or effect in their production. In fact, the number of these cytokines and
chemokines produced by both the strains of mice for similar treatments doesn't look too
di fferent.
The other group of cytokines and chemokines showing similar trends includes the
IL-I ~, TNF-n, Eotaxin, GM-CSF, RANTES, MlP-lr.t, MlP-1~ and LIF. Whi le the
production of these cytokines and chemokines showed huge suppression due to ethanol
treatment in both the wi ld-type and mutant mice, it looks like the absence of TLR4 also
played a ro le because the production of cytokines and chemokines in the mutant strain of
mice was very low compared to the wild-type mice for both the treatment~.
Whi le the IL-IO production in wi ld-type mice was enhanced due to the ethanol
treatment, its production in the mutant mice wa~ very low and there wasn't any
significant difference in its production due to the ethanol treatment. It is interesting to
note that the enhancement of LPS-induced IL-IO production by ethanol has been
previously reported using human subjects a lso ( 134). Thus it seems likely that this is a
general phenomenon. For the IL-1 7 cytokines, while its production was very significantly
decreased due to the ethanol treatment in the wi ld-type mice, the mutant mice showed an
opposite effect, i.e., the ethanol treated mice produced more IL-17 cytokines than the
non-ethano l mice, even though the di fference was not significant in nature.
Considering some cytokines like IL-6 and IL-12 generally enhance immunity and
IL-10 is suppressive in most systems, the net result of ethano l induced changes in these
parameters would probab ly be immunosuppressive. These results are genera lly consistent
with report~ from other studies indicating suppression of proinflammatory cytokines
(135) and increased IL-IO ( 136) associated with a lcoho l consumption (137).
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It is well recognized that IL-10 can inhib it protective immune response to

infections ( 138). It has been shown that the trauma, bum, and major surgery-induced
immuno-depression, which pred ispose to infectious comp lications, is related to IL-1 0
over-expression (139, 140, 141). It has also been shown that IL-1 0 controls inflammatory
processes by suppressing the expression of proinflammatory cytokines, chemokines,
adhesion molecu les, as well as antigen-presenting and co-stimulatory molecu les in
monocytes/macrophages, neutrophi ls, and T cells ( 138). Cons idering the ability ofIL-10
to inhibit monocyte function, it is likely that e levated IL-10 levels contribute to the
disturbed ce llular immune response observed after acute alcohol treatment. A~ a ll of the
inflammatory proteins are transcriptionally controlled by NF-KB it has been suggested
that IL-1 0 may exert a significant part of its anti-inflammatory properties by inhibiting
this transcription factor ( 142, 143).
On the other hand, IL-10 has a lso protective effects in infection because it
prevents an uncontro lled inflammatory response to infectious triggers. IL-ID-deficient
mice have been observed to show a prolonged inflammatory response to acute

Pseudmnonas challenge resulting in neutrophi l accumulation in the lung. This
observation suggests that IL- IO deficiency might contribute to prolonged inflammatory
responses early in cystic fibrosis, a lung disease that is characterized by a neutrophi lic
infi ltrate that is excessive relative to the burden of infection (144). Overexpression of ILIO prevents mice from endotoxin or bacteria-induced septic shock whereas lack of IL- I 0
increa~es the susceptib ility to toxin-related shock ( 138, 145). IL-IO also protects against
experimental group B streptococcal arthritis (146). Similar protective properties of IL- I 0
were observed for gastrointestinal helminth infections (147). Because IL-1 0 expresses
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potent immuno-modulatory properties it can modulate the course of infections. The main
target of IL-IO is macrophages, and these ce lls play a central ro le in infections, as a target
for pathogens and in the activation of both specific and innate immune response.
Many studies have demonstrated that IL-17 appears to be an important mediator
of inflammation, especially in neutrophil-dominated responses to bacterial challenge
(148). This connection is intriguing given that expression of IL-17 is restricted to
memory T cells, wh ich are associated with an adaptive immune response, while
neutrophils are viewed primarily as mediators of innate immunity. It has been
hypothesized that by secreting IL-17, which subsequently induces chemokines and
granulopoietic factors, memory T cells may enhance faster and more effective
recruitment ofneutrophils (149). In this respect IL-17 may serve as a modulator of early
immune responses to pathogens, and as such may be an important element of host
defense. On the other hand, the overproduction of IL-17 may aggravate inflammatory
reactions and contribute to tissue injury. In such situations IL-17 may be viewed as a
potential target for therapeutic intervention, and this approach is now intensive ly being
explored by the pharmaceutical industry.
Overall, the result~ obtained here demonstrate that ethanol treated mice exhibit
decreased clearance of bacteria and produce lesser amounts of most pro-inflammatory
cytokines. This suggests that ethano l inhibit~ the initial inflammatory response to E. coli
and this leads to decreased clearance of bacteria. Large number of macrophages in the
peritonea l flu id indicates the decrea~ed attraction of neutrophils to the peritoneal cavity
and decrea~ed c learance of bacteria by macrophages and neutrophils in the peritoneal
cavity, hence the increased mortality.
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TLR4 is dispensable for survival in E. coli sepsis. TLR4 contributes to lethality in
wild-type mice. A hypo-functiona l TLR4 allows surviva l in mice. LPS stimu lates a
unique and critical pathway of innate immune responses that is independent ofTLR4 and
results in early neutrophi l infiltration and enhanced bacterial clearance. In summary,
cytokines are key modulators of inflammation. They participate in acute and chronic
inflammation in a comp lex network of interactions. Several cytokines exh ib it some
redundancy in function and share overlapping properties as well as subun its of their cell
surface receptors. Better understanding of the pathways regu lated by cytokines will allow
the identification and/or development of agents for improved modulation of the
inflammatory response for the treatment of autoimmune and other infectious disea~es.
In conc lusion, attraction of TLR4 signaling pathways by LPS is a critica l

upstream event in the pathogenesis of gram-negative sepsis making TLR4 an attractive
target for novel antisepsis therapy. Recent studies have shown that anti-TLR4 antibodies
inhibited intracellu lar signaling, markedly reduced cytokine production and protected
mice from letha l endotoxic shock and E. coli sepsis when administered in a prophylactic
and therapeutic manner upto 13 h after the onset of bacterial sepsis ( 150). These
experimental data provide strong support to the concept of TLR4 targeted therapy for
gram-negative sepsis ( 151). At a time when most anti-sepsis clinical trials have
frustratingly yielded negative result~, these experimenta l data provide strong support to
the TLR4-targeted therapy currently underway in patients with gram-negative sepsis.
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